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conducted probabilistic sensitivity analysis. ConClusions: The cost-effectiveness 
of a lung cancer screening program varies widely and seems to largely depend on 
several key model parameters. Improved risk stratification might enhance the cost-
effectiveness of such a program.
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objeCtives: Evzio is a naloxone autoinjector indicated for lay overdose reversal in 
emergency treatment of known or suspected opioid overdose. The cost effectiveness 
of prescribing Evzio for “lay overdose reversal” was compared to “no lay reversal” 
using a health system perspective over one year. Methods: A decision analysis 
model was built using outcomes data obtained from randomized clinical trials and 
publicly available cost data. Adults at risk of heroin overdose in the US were included 
in the model. The primary outcome was Quality Adjusted Life Year (QALY). All data 
were subject to sensitivity analyses. Results: In the base case analysis, Evzio was 
found to cost health systems an extra $24,126 for every additional QALY saved due 
to overdose. Sensitivity analyses of variables found that the model was sensitive to 
the probability of emergency medical services being called if no Evzio was given, 
the probability of an overdose being witnessed, and the probability of survival if 
no medical treatment was given. ConClusions: The cost per QALY saved in pre-
scribing the naloxone autoinjector, Evzio, for patients at risk of opiate overdose is 
within acceptable cost effectiveness values for new therapies. When administered 
by friends, family members, and other witnesses of an opioid overdose, Evzio can 
be cost-effective.
PMD51
estiMating the Cost-effeCtiveness of left atrial aPPenDage Closure 
CoMPareD to warfarin for stroke Prevention in atrial fibrillation
Shih V., Devine B.
University of Washington, Seattle, WA, USA
objeCtives: Atrial fibrillation (AF) is an arrhythmia that increases stroke risk. 
Left atrial appendage (LAA) occlusion with a LAA closure device is the first non-
pharmacologic strategy to undergo randomized, warfarin-controlled trials. It has 
demonstrated non-inferiority to the current standard, warfarin, for stroke and 
systemic embolism prevention. The objective of this study was to evaluate the 
cost-effectiveness of LAA closure relative to chronic warfarin therapy for stroke 
prevention in AF patients at elevated stroke risk. Methods: A Markov model was 
constructed from the payer perspective assuming a cohort of AF patients aged 65 
with a CHADS2 score≥ 2 at model entry. Clinical inputs were obtained from pub-
lished trials. Utilities were obtained from published studies assessing quality-of-
life in AF patients. Costs were obtained from published literature. Using quarterly 
cycles, the model was run over the patients’ remaining lifetime summing total costs 
and total quality-adjusted-life-years (QALYs) for each arm. Results: Total QALYs 
gained for the warfarin and device arms were 11.58 and 11.76, respectively. Total 
costs for the warfarin and device arms were $84,100 and $89,400, respectively. The 
base-case ICER for LAA closure compared to warfarin was $29,600/QALY. The model 
was most sensitive to underlying rates of stroke and intracranial hemorrhage (ICH) 
and the relative risk of stroke and ICH in the device arm compared to warfarin. It 
was relatively robust to costs and utilities. Monte Carlo simulation with 10,000 itera-
tions demonstrated LAA closure was cost-effective in 50% and 54% of simulations 
at thresholds of $50,000/QALY and $100,000/QALY. ConClusions: Though not yet 
available in the US, trial data suggests LAA closure is an option for anticoagulant-
eligible AF patients. It is estimated to be cost-effective at previously acceptable 
willingness-to-pay thresholds, but uncertainty around the ICER suggests a need 
for more precise parameter estimates. It remains a novel mechanism to improve 
outcomes in undertreated AF patients.
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objeCtives: Efforts to reduce the tuberculosis (TB) burden in many countries 
have recently focused on screening high-risk groups for latent TB infection (LTBI). 
Clinicians generally use the tuberculin skin test (TST) or interferon-gamma release 
assay (IGRA) to aid in LTBI diagnosis. We performed a systematic review of cost-
utility analyses in this area. Methods: Five electronic databases were used to iden-
tify studies. Study quality was assessed using the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS). Population, setting, model type, perspec-
tive, costs, screening and treatment parameters, and incremental cost-effectiveness 
ratios (ICERs) were extracted. All costs were adjusted to 2013 US dollars, with ICERs 
< $20,000 considered highly cost-effective, ICERs between $20,000 and $100,000 
moderately cost-effective, and ICERs > $100,000 not cost-effective. Results: Of 
415 studies identified, 8 were included in the analysis, with 7 using Markov mod-
els and 1 using decision analysis. The decision to screen and how to screen for 
LTBI was evaluated in 5 studies, while the remaining three only evaluated how 
to screen. Perspectives used were societal (n= 4), healthcare program (n= 2), and 
healthcare system (n= 2). Studies evaluating immigrants found adult screening 
highly cost-effective with a TST (n= 1) and moderately cost-effective with an IGRA 
(n= 1). Screening of the foreign-born (n= 1) was moderately cost-effective with an 
IGRA until 44 years of age. Screening for HIV was found to be highly cost-effective 
with a TST (n= 3) and moderately cost-effective with an IGRA (n= 1). Screening in 
those with renal diseases (n= 2) and diabetes (n= 1) was found to be not cost-effec-
tive; screening in other immunocompromised populations was not cost-effective 
(n= 1). ConClusions: Screening of HIV patients with a TST is highly cost-effective 
and screening of immigrants and foreign-born with an IGRA is moderately cost-
sant medication for the treatment of adults with MDD who have failed at least two 
adequate courses of antidepressants. Methods: A three-year Markov microsimu-
lation model with two-month cycles was used to compare the costs and quality-
adjusted life years (QALYs) of rTMS and a mix of antidepressants (including selective 
serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, 
tricyclics, noradrenergic and specific serotonergic antidepressants and monoam-
ine oxidase inhibitors). The model synthesized data sourced from a meta-analysis, 
published literature, national cost reports and expert opinions. Incremental cost-
utility ratios were calculated and uncertainty of the results was assessed using 
univariate and probabilistic sensitivity analyses. Results: Compared with anti-
depressant medication therapy, rTMS is a dominant/cost-effective alternative for 
patients with treatment-resistant depressive disorder. The model predicted that 
QALYs gained with rTMS was higher than for antidepressant medications (1.25 ver-
sus 1.18 QALYs) while costs were slightly less (AUD 31,003 versus AUD 31,190). The 
treatment response rate, using the Hamilton Depression Rating Scale 17, was 16.8% 
for antidepressant medications and 37.5% for rTMS. In the Australian context at the 
willingness-to-pay threshold of AUD 50,000 per QALY gain, the probability that rTMS 
was cost-effective was 73%. Sensitivity analyses confirmed the model stability and 
superiority of rTMS compared with antidepressant medications. ConClusions: 
While both antidepressant medications and rTMS are clinically effective treatments 
for MDD, rTMS is shown to outperform antidepressants in terms of cost-utility 
for patients who have failed at least two adequate courses of pharmacotherapies. 
The study shows that rTMS is a cost-effective therapy alterative for patients with 
treatment-resistant depression without the many side-effects of pharmacotherapy.
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objeCtives: Patients with non-ST elevation myocardial infarction are managed 
based visual assessment of coronary angiography, which can be inaccurate and 
subjective. A randomized pilot trial has investigated an alternative approach using 
physiology-guided management with fractional flow reserve that may optimize 
outcomes. Objective was to estimate the cost-effectiveness of FFR-guided manage-
ment vs. coronary angiography. Methods: A trial-based economic evaluation was 
conducted (n= 350). We adopted a UK National Health Service perspective. Part I of 
the analysis used raw, unadjusted costs and QALYs assembled using individual 
resource use and EQ5D responses from the RCT. Part II used statistical modelling 
to model the effect pathway of FFR by conditioning total costs and QALYs on the 
treatment decision (coronary artery bypass graft (CABG), medical therapy and per-
cutaneous coronary intervention (PCI)). Results were then applied to treatment 
decision distributions following FFR or standard care management. Uncertainty in 
GLM coefficients, unit cost parameters and sampling were incorporated using boot-
strapping and Monte Carlo methods. Results: FFR reduced revascularization by PCI 
or CABG (OR 0.52; 95%CI: 0.28 – 0.94; p= 0.022). Part I: FFR led to a mean cost savings 
(£8,253 vs. £8,603; difference: –£305 [SD= £519]). Likely drivers of cost savings were 
length of stay (-£331 [£342]) and index year health events (-£217 [£223]). However, 
low information size contributed to their large imprecision. Incremental QALYs 
were comparable (0.811 vs. 0.799; diff: 0.013 [0.023]). Part II: FFR led again to a mean 
cost savings (£8,328 vs. £8,532; difference: –£204 [£305]) and comparable incremen-
tal QALYs (0.801 vs. 0.806; diff: –0.005 [0.004]). The probability of cost-effectiveness 
remained comparable over common willingness-to-pay (70-75%). ConClusions: 
Early evidence suggests FFR may be cost saving and comparable in QALYs. However, 
considerable uncertainty persists. We also prescribe specific design considerations 
for a future trial, including information size suggestions, follow-up frequency and 
outcomes to aid modelling/lifetime extrapolation.
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objeCtives: Lung cancer is the leading cause of cancer related mortality in North 
America. This is attributable to it often being diagnosed at an advanced stage. Low 
dose computed tomography (LDCT) is a tool that can be used to potentially detect 
lung cancer at an earlier stage thereby improving patient outcomes. Recently, the 
National Lung Screening Trial (NLST) has shown that this method of screening 
can produce significant mortality reductions; however, whether such a program is 
cost-effective has not yet been well-established. Methods: We searched MEDLINE, 
EMBASE, EBM Reviews - Health Technology Assessment, the National Health Service 
(NHS) Economic Evaluation Database, and the Cochrane Database of Systematic 
Reviews. We included studies that presented a cost-effectiveness analysis of LDCT as 
a method of screening for lung cancer. Studies published prior to 2000 were excluded 
based on advances in imaging technologies. Costs are presented in 2012 United 
States dollars. Results: Thirteen studies were identified that met the criteria for 
inclusion. Ten studies were from the United States, and one each from Australia, 
Israel, and Japan. Most studies evaluated an annual screening program while four 
studies evaluated one time only screening. Incremental cost-effectiveness ratios 
(ICERs) were extracted for comparison and varied markedly between $8 186/LYG to 
$195 758/LYG (life year gained) or for quality-adjusted life years (QALYs): $1 494/QALY 
to $150 772/QALY. The model results seemed to be sensitive to several parameters 
including: the prevalence of lung cancer, the cost of LDCT screening, inclusion and 
characteristics of a smoking cessation program, the stage at which lung cancer was 
detected, and the lead-time associated with screening. Only one identified study 
